Ipamorelin Dosing & Protocols — Research Reference

Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) and selective agonist of the ghrelin (GHS-R1a) receptor. This guide compiles the dosing tiers, reconstitution practice, and scheduling patterns most commonly cited in published preclinical research on the GH/IGF-1 axis.

Reconstitution for Research

Ipamorelin is typically supplied as a lyophilized powder in 2 mg or 5 mg vials. Standard laboratory practice reconstitutes the vial with 2 mL of bacteriostatic water, yielding concentrations of 1 mg/mL or 2.5 mg/mL respectively. At a U-100 insulin-syringe scale, 10 IU equals 0.1 mL — at 1 mg/mL that delivers 100 mcg per 10 IU. Refrigerate reconstituted solution at 2–8 °C and use within the stability window documented on the certificate of analysis (commonly 21–30 days).

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Entry / pulse characterization | 100 mcg per dose | Threshold for observable GH pulse in adult-rodent and translational models | | Standard GH-pulse studies | 200–300 mcg per dose, BID–TID | Most frequently cited tier; often paired with a GHRH analogue | | High-dose pharmacology | 300–500 mcg per dose | Used in acute pulse-amplitude and dose-response work |

Receptor desensitization plateaus the GH response above approximately 1 mcg/kg in most ghrelin-receptor studies; further dose escalation does not proportionally increase GH output.

Scheduling

Published protocols use subcutaneous injection as the most-cited route. Timing patterns cluster around three windows that exploit endogenous GH-pulse architecture:

• Pre-sleep dose — leverages the nocturnal GH pulse.
• Fasted morning dose — minimizes blunting from postprandial somatostatin/insulin elevation.
• Post-exercise dose (in exercise models) — captures the exercise-induced GH pulse.

Two-a-day (AM/PM) and three-a-day (AM/mid-day/pre-sleep) schedules are both represented in the literature; three-a-day is more common in acute pulse-amplitude studies.

Synergistic Stacking with GHRH Analogues

The most replicated stack in GH-axis research combines ipamorelin (GHRP class — ghrelin receptor) with a GHRH analogue (sermorelin, CJC-1295, or tesamorelin — GHRH receptor). The two receptor systems converge on somatotrope cAMP/calcium signalling and produce synergistic — not additive — GH release. Typical co-dosing pairs 100–300 mcg ipamorelin with 100–300 mcg CJC-1295 (no DAC) or 200–500 mcg sermorelin per pulse.

Cycling in the Published Literature

Long-duration GHS exposure produces receptor downregulation in cellular and rodent models. Published cycling patterns typically run 8–12 weeks on with 4-week washout, or continuous use at conservative pulse doses with periodic stimulation-test verification.

Quality and Identity Verification

Mass-spec (LC-MS) confirmation of molecular weight (711.85 Da, free base) and HPLC purity ≥98% are the two most-cited acceptance criteria for ipamorelin research material. Endotoxin testing is required for parenteral animal models.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption, prophylactic, or therapeutic use.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
2. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149–S159.
3. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308.